Contemporary systematic review and meta-analysis of outcomes associated with femoropopliteal above-the-knee nonautologous surgical bypass.

J Vasc SurgMay 14, 2026 (epub)
Clinical ResearchVascular Surgery

Anne M Ryschon, Ami Sood, Abigail M Garner et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated outcomes of above-the-knee femoropopliteal nonautologous surgical bypass in 2083 patients. The study found primary patency rates of 80% at 12 months and 61% at 36 months. The analysis provides a contemporary benchmark for clinicians considering surgical bypass for long-segment or heavily calcified lesions.

Key findings

  • 12-month primary patency rate was 80% (95% CI, 0.77-0.82).
  • 36-month secondary patency rate was 68% (95% CI, 0.56-0.78).
  • 12-month limb salvage rate was 97% (95% CI, 0.91-1.00).
  • Mortality rates increased from 7% at 6 months to 24% at 36 months.

Why it matters

Understanding the contemporary outcomes of nonautologous surgical bypass is crucial for clinicians when evaluating treatment options for patients with femoropopliteal disease, particularly in cases where endovascular therapy may not be suitable.

Source

Published in J Vasc Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Vascular Surgery

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.